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Available online 24 January 2015Abstract We evaluated the characteristics of bone marrow stromal cells (BMSCs) and hematopoietic cells (HCs) from patients
of myelodysplastic syndrome (MDS, n = 21) and acute myeloid leukemia (AML, n = 58), and compared the results with control
BMSCs derived from healthy donors (n = 8). The patient BMSCs had lower proliferative activity than that of the controls due to
increased senescence. This retarded proliferation induced failure to obtain enough metaphase cells for karyotyping in patient
BMSCs (10%). Patient BMSCs were genetically altered which was demonstrated by chromosome abnormalities in 5% of the
patients (one MDS and three AML), whereas no clonal abnormalities were detected in the controls. The most common
abnormality of the BMSCs was an extra chromosome 5, followed by an extra chromosome 7 and balanced translocations. The
proportion of the abnormal metaphase cells was low (17.8%). We also analyzed the epigenetic changes of long interspersed
nucleotide element 1 (LINE-1) repetitive element and CDKN2B using pyrosequencing. The quantitative measurement of global
LINE-1 methylation demonstrated that patient BMSCs revealed global hypomethylation (68.2 ± 3.8) compared with controls
(72.9 ± 3.4, P b 0.001) and that the global hypomethylation of BMSCs were more significant in AML than in MDS patients
(67.9 ± 3.8, 69.4 ± 4.2, respectively). These findings seem worthy of further evaluation of their association with ineffective
hematopoiesis and leukemogenesis.
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Bonemarrow (BM) is the site of hematopoiesis and is composed
of hematopoietic cells (HCs) and their niche, which includes
BM stromal cells (BMSCs), osteoblastic cells, osteoclasts,
skeletal stem cells, endothelial cells, endosteal monocytes/
macrophages, and sympathetic nervous system neurons
(Sacchetti et al., 2007; Smith and Calvi, 2013). The hemato-
poietic niche is the physical locale of the microenvironment
that regulates self-renewal, proliferation and differentiation
of HCs and protects HCs from oncogenic, physical and
chemical damage (Oh and Humphries, 2012). BMSCs have
been reported to control hematopoiesis through the produc-
tion of cytokines that are active in effective hematopoiesis
and to support T cell and B cell survival by preventing
apoptosis (English, 2013; Majumdar et al., 2000).
Myelodysplastic syndrome (MDS) and acute myeloid leukemia
(AML) are HC neoplasias, and their leukemogenic process is
initiated by the accumulation of inherited and randomly acquired
genetic aberrations. Cytogenetic abnormalities and gene muta-
tions inMDS andAML arewell-knownandhavebeen recognized in
the World Health Organization classification (Swerdlow et al.,
2008) and revised international prognostic scoring system for
MDS (Greenberg et al., 2012). In addition, many hematologic
neoplasias also acquire epigenetic changes, which may have a
profound effect at the level of gene expression (Bonifer and
Bowen, 2010; Jelinek et al., 2011). For example, the inactivation
of tumor suppressor genes by promoter hypermethylation
contributes to the initiation and progression of MDS and AML
(Bies et al., 2010; Cechova et al., 2012).
A few studies have characterized abnormalities of the BM
microenvironment in hematologic malignancies. Some reported
that BMSCs in MDS are cytogenetically and functionally normal
and maintain their original function of supporting normal
hematopoiesis (Flores-Figueroa et al., 2008; Klaus et al., 2010;
Soenen-Cornu et al., 2005), whereas others have reported that
BMSCs in MDS and AML showed numerical and structural
chromosomal abnormalities, especially the loss of chromosomes
(Blau et al., 2007; Flores-Figueroa et al., 2005). Recent data
demonstrated that BMSCs of MDS and AML patients have distinct
genetic abnormalities compared with leukemic blasts and that
these genetic alterations in BMSCs may constitute a particular
mechanism of leukemogenesis and affect patient prognosis
(Blau et al., 2011). In addition, Geyh et al. defined
epigenetic changes, including a specific methylation
pattern of MDS-derived BMSCs, and their association with
the functional properties of BMSCs (Geyh et al., 2013).
In this study, we evaluated genetic and epigenetic abnor-
malities of HCs and BMSCs in MDS and AML patients. Genetic
changes were analyzed using conventional cytogenetics, fluo-
rescence in situ hybridization (FISH) and array comparative
genomic hybridization (aCGH) techniques. Epigenetic changes
were analyzed by measurement of global and focal methylation
using pyrosequencing.
Patients and methods
Patients
This study included a total of 79 patients (21 with MDS and 58
with AML) who were diagnosed and treated in the CatholicBlood and Marrow Transplantation Center. The diagnoses
were based on the World Health Organization criteria
(Swerdlow et al., 2008). Multicolor flow cytometry was
performed using myeloid lineage antigens, including CD33,
CD13, CD117 (CKIT), CD14, CD64, and CD41 (BD Biosciences/
Pharmingen, CA, USA), to establish the blast lineage.
Multiplex RT-PCR was performed to detect the presence of
common genetic rearrangements using a HemaVision kit
(Bio-Rad Laboratories, CA, USA). Signed informed consent was
obtained from all patients, and this study was performed in
accordance with the Declaration of Helsinki and approved by
our local institutional review board (SCMC07BR131). BMSCs
from eight healthy donors, four of which were isolated and
cultured in our laboratory and four of which were obtained
from the Texas A&M Health Science Center College of
Medicine Institute for Regenerative Medicine at Scott &
White (Temple, TX, USA), served as the controls for this
study. The characteristics of the control and patient cells
are summarized in Table 1.
Isolation, culture, and characterization of BMSCs
BMSCs were isolated from fresh BM aspirates using the
RosetteSep human mesenchymal stem cell enrichment cocktail
(StemCell Technologies, Vancouver, BC, Canada) at the time of
initial diagnosis. In brief, 50 μL RosetteSep solution and 2 mL
BM aspirate weremixed and incubated at room temperature for
20 min. After addition of Ficoll-paque Plus (Amersham Biosci-
ence, Freiburg, Germany) and centrifugation, the unwanted
cells were precipitated, and the BMSC-enriched fraction was
collected and seeded at an initial concentration of approxi-
mately 1 × 106 cells/mL. The cells were cultured in α-modified
minimum essential medium (α-MEM, Gibco BRL®, NY, USA)
supplementedwith 10% fetal bovine serum (Gibco BRL®) and 1%
penicillin–streptomycin (Gibco BRL®) at 37 °C and 5% CO2.
Non-adherent cells were removed and the media were
changed every three to four days until the BMSCs reached
70% confluency. To define the characteristics of BMSCs,
immunophenotypic features were analyzed with antibodies
against CD73, CD90, CD105, HLA-DR, CD11b, CD79a, CD34, and
CD45 (BD Biosciences/Pharmingen). The samples were ana-
lyzed on a FACS Aria, and the resulting data were processed
using CellQuest software (BD Biosciences). BMSCs at passages
3 to 4 were used for the experiments. The proliferation
activity of BMSCs was analyzed to compare growth kinetics
between the control and patient BMSCs using representative
specimens (4 normal samples and 3 patients; 2 MDS and 1
AML). Population doubling time (PDT) was used as an indicator
of the proliferative activity of the BMSCs.
Senescence-associated β-galactosidase
staining assay
Beta-galactosidase, which is specifically expressed in
senescent cells and corresponds to an accumulation of
lysosomal endogenous β-galactosidase, is active at pH 6.0
(Debacq-Chainiaux et al., 2009). We evaluated the expres-
sion of β-galactosidase using the senescence-associated β-
galactosidase (SA-β-gal) staining kit (Cell Signaling Technology,
Boston, MA, USA), according to the manufacturer's instructions.
The percentage of blue-stained senescent cells was obtained by
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microscope.In vitro differentiation
Each sample was differentiated as follows: the cells were
harvested by trypsinization and seeded in 6-well culture
dishes (BD Biosciences) at a concentration of 1 × 105/well.
After expanding the BMSCs in growth medium to 70%
confluency, the growth medium was replaced with differ-
entiation induction medium. The cells were incubated at
37 °C for three weeks, and the fresh medium was replaced
every three days. To evaluate adipogenic differentiation of
the BMSC samples, the cells were cultured in adipogenesis
differentiation basal medium (Gibco) containing an adipogen-
esis supplement, such as 1 μM dexamethasone, 0.5 mM
isobutylmethylxanthine, and 200 μM indomethacin. The cyto-
plasmic inclusions of neutral lipids were then stained with oil
red O (Sigma-Aldrich, St. Louis, MO, USA). The cells were fixed
with 4% paraformaldehyde (PFA) solution and incubated in
60% isopropanol for 5 min at room temperature; then, the
isopropanol was aspirated. The cells were stained with oil red O
(Sigma) solution for 30–60 min.
For chondrogenic differentiation, 4 × 105 cells of the BMSC
samples were added to 15-mL conical tubes (BD Biosciences),
which were centrifuged at 150 g for 5 min. Then, the cells
were cultivated in chondrogenic induction medium (Gibco) for
four weeks. Control cells were maintained in standard culture
medium with 10% FBS during the same time period. To assess
chondrogenic differentiation, pellets were fixed in 4% formal-
dehyde and embedded in paraffin. The sections were stained
with Alcian Blue (Sigma-Aldrich).
Osteogenic differentiation was assessed by incubating the
cells in osteogenesis differentiation medium (Gibco) containing
an osteogenesis supplement, such as 100 nM dexamethasone,
50 μM ascorbic acid-2-phosphate and 10 ng/mL recombinant
human bone morphogenetic protein. Osteoblasts were identi-
fied by visualizing calcium deposits using the von Kossa method
and a calcium kit (Polysciences, Warrington, PA, USA). The cells
were fixed with 4% PFA solution and incubated in 3% silver
nitrate solution under UV light for 1 h. After rinsing, the cells
were incubated in 5% sodium thiosulfate for 2 min.Table 1 Demographics of enrolled individuals.
Control MDS
Number 8 21
Age, years 32.3 ± 15.1 47.9
Sex (M/F) 2/6 11/1
Diagnosis RCM
RAEB
RAEB
IPSS-R Very
Low
Inter
High
Very
Abbreviations: MDS, myelodysplastic syndrome; AML, acute myeloid le
RAEB, refractory anemia with excess blasts; APL, acute promyelocyticCytogenetic analysis of HCs and BMSCs
Karyotyping of HCs and BMSCs was performed by a standard
method of G-banding and described by the International System
for Human Cytogenetic Nomenclature (ISCN), 2009 (Willatt and
Morgan, 2009). To confirm cytogenetic abnormalities identified
by G-banding, FISH was performed with appropriate probes,
according to the manufacturer's recommendations. The follow-
ing probes were used: LSI EGR2/D5S23, D5S721, D7S486/CEP7,
CEP8, CEPX/CEPY (Abbott Laboratories, IL, USA), MYBL2, and
D20S150/D20S108 (Cytocell, UK).
Array comparative genomic hybridization
Briefly, genomic DNAwas extracted fromHCs and BMSCs using a
QIAamp DNA Blood Mini Kit (Qiagen, CA, USA). Sex-matched
DNA from Promega (Napeen, Canada) was used as the reference
DNA. The patient and reference DNAs were labeled with Cy3
and Cy5 dyes, respectively, by random primer labeling. Labeled
genomic DNA was co-hybridized to the NimbleGen CGX
12 × 175 K array (Roche NimbleGen Inc., Madison, WI, USA).
The arrays were washed, and fluorescent signals were acquired
with a NimbleGen MS200 scanner (Roche NimbleGen Inc.). The
data were analyzed using DEVA Project Manager 1.0.2 software
(Roche NimbelGen Inc.).
Pyrosequencing for quantitative analysis of long
interspersed nucleotide element 1 (LINE-1) repetitive
element and CDKN2Bmethylation
Bisulfate conversion was performed with 2 μg DNA using the
EpiTect Bisulfite Kit (Qiagen) according to the manufacturer's
instructions. Denaturation was performed at 95 °C for
5 min. PCR and pyrosequencing primers were designed using
PSQ Assay Design software (Biotage, Uppsala, Sweden)
(Supplementary Table S1). The PCR mixture contained 100 ng
bisulfate-converted DNA, 10× PCR buffer, 10 mM dNTP, DNA
Taq polymerase, and 10 pmol of the forward and 5′ biotinyl-
ated reverse primers in a 25 μL reaction. The PCR conditions
were as follows: pre-denaturation at 95 °C for 15 min,
followed by 45 cycles of 95 °C for 30 s, 60 °C for 30 s, and
72 °C for 30 s, and a final extension at 72 °C for 5 min.AML
58
± 14.1 38.7 ± 19.2
0 29/29
D (n = 7) AML with t(8;21) (n = 8)
-1 (n = 4) APL with t(15;17) (n = 8)
-2 (n = 41) AML with inv(16) (n = 5)
AML NOS (n = 37)
low (n = 1)
(n = 3)
mediate (n = 10)
(n = 5)
high (n = 2)
ukemia; RCMD, refractory cytopenia with multilineage dysplasia;
leukemia; NOS, not otherwise specified.
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kit (Qiagen) and PyroMark ID system™ (Biotage, Uppsala,
Sweden) according to the manufacturer's recommendations.
CpG site quantification was performed with the new methyla-
tion software PyroQ-CpG™ (Boptage) (Supplementary Fig. 2).
The criteria for Pyrogram selection were as follows: sufficient
peak height of N15 units (calculated by the software),
symmetric peaks without any irregularities or side peaks, wide
reading length with high reliability, and absence of significant
signals at the position of the bisulfate treatment control.
Statistical analysis
The LINE-1 and CDKN2Bmethylation percentages in the normal
and patient BMSCs were compared by the Mann Whitney U test.
The methylation percentages in BMSCs were compared with
those of the corresponding HCs by the Wilcoxon signed rank
test. The correlations of the LINE-1 and CDKN2B methylation
percentages between the patient BMSCs and their correspond-
ing HCs were determined using Spearman's rank method.
Significance was defined as P b 0.05. All calculations were
performed using Medcalc software 9.0 (Medcalc, Mariakerke,
Belgium).Results
BMSCs from patients demonstrated impaired
growth kinetics
The isolated BMSCs from both healthy donors and patients
were adherent cells with typical fibroblast-like morphology.
They were positive for CD73, CD90 and CD105 (N95% of
cells), negative for HLA-DR, CD11b, CD79a, CD34 and CD45
(b2% of cells) and possessed the potential to differentiate
into adipocytes, chondroblasts and osteoblasts (Supplemen-
tary Fig. S1).Passage 2
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Figure 1 Proliferation activity of control and patient bone marrow
in patient BMSCs after 3rd passage (*P = 0.040, **P = 0.001). (b) Repr
in BMSC myelodysplastic syndrome (MDS) patient (lower) than in con
also observed in patient BMSCs in later passage. (c) Senescence as
revealed higher positive cells than control.PDT was increased with increasing passages. The patient
BMSCs had retarded proliferation rateswhen comparedwith the
control BMSCs indicated by a longer PDT after passage 3 (patient
51.84 ± 6.56 vs. control 42.53 ± 6.12, P = 0.040), and this
difference was increased with increasing passages (patient
PDT: 259.80 ± 56.85 vs. control PDT: 111.67 ± 53.45 at passage
7, P = 0.001). SA-β-gal staining revealed that a greater number
of patient BMSCs entered senescence than control BMSCs
(30.3 ± 0.5% vs. 8.9 ± 2.1%) at passage 3. Cells were considered
to be senescent if they were stained blue which were usually
enlarged and had a flat shape. Retarded growth rates were also
explained by these SA-β-gal staining results (Fig. 1).
Genetic abnormalities of BMSCs from patients
Genetic abnormality enhancement has beenwell-documented
in HCs isolated from patients presenting with MDS and AML.
Accumulated data has shown that BMSCs play a critical role in
many aspects of HC growth, and this raises the question
of whether BMSC and HC genetic alterations are correlated.
We investigated patient BMSCs to detect increased genomic
instability. In addition, we compared the findings of patient
BMSCs with their paired HCs to identify correlations in
genomic changes. The genetic findings were evaluated by
cytogenetic analysis, FISH, and aCGH. The cytogenetic analysis
was successfully performed using a conventional G-banding
technique in all patient HCs. We obtained enough metaphase
cells (at least 15) in all control BMSCs derived from healthy
donors, and all of the control BMSCs were found to have
normal karyotypes. On the other hand, we failed to obtain
enough metaphase cells in the BMSC samples of eight
patients (10.1%; one MDS and seven AML), mainly because
of their low proliferative activities.
A cytogenetic abnormality is usually considered to be
clonal when more than two metaphase cells exhibit it. We
found clonal cytogenetic abnormalities in four patient BMSC
samples, and the percentage of abnormal metaphase cellsPassage 4 Passage 7 SA-β-gal staining 
(c)
stromal cells (BMSC). (a) Population doubling time is prolonged
esentative pictures of BMSCs during culture. Cell density is lower
trol (upper) at 4th and 7th passages. Wide and granular cells are
sociated β galactosidase staining in MDS patient BMSCs (lower)
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MDS patients, clonal cytogenetic abnormalities were identi-
fied in 61.9% (n = 13) of HCs and 5.0% (n = 1) of BMSCs. An
MDS patient (R86) with a normal HC karyotype had an
abnormal BMSC karyotype, including t(4;15) (q12;q24),
tetrasomy 5, and trisomy 7, 8, and 9, in 10 out of 50
metaphase cells (Fig. 2a). We used FISH and aCGH to
evaluate whether this aberration was found in both HCs
and BMSCs and confirmed that only BMSCs had the
aberration. Among AML patients, cytogenetic abnormalities
were identified in 58.6% (n = 34) of HCs and 5.9% (n = 3) of
BMSCs. An AML (A62) patient with a normal HC karyotype
displayed trisomy 5 in three of 15 analyzed BMSCs. This
karyotype abnormality was only detected in BMSCs; this was
confirmed by FISH but was not confirmed by aCGH because
of the low mosaicism (Fig. 2b). For an AML patient (A106)
with HCs displaying monosomy 7 and inv(3) (p25q29), the(a) (b)
①
③
Figure 2 Representative karyotype, fluorescence in situ hybridiza
results. (a) Normal karyotype of hematopoietic cells (HC) (upper)
(medium) from a patient with refractory anemia with excess blasts-2
pattern and BMSCs showing gain of whole chromosome 5. (b) Normal
patient with acute myeloid leukemia (AML) with maturation (A62). F
(G) and 2 red signals (R) in HC (①, ②) (upper) and coexistence of a
Abnormal karyotype including monosomy 7 in HC (upper) and mosa
patient with AML without maturation (A106). aCGH of chromosome 7
normal pattern.corresponding BMSCs displayed trisomy 5 and 1q gain
(Fig. 2c). The numerical aberrations observed in HCs and
BMSCs were verified by FISH.
aCGH results were available for seven healthy controls
and 18 MDS and 51 AML patients. In HCs, four MDS (22.2%)
and 14 AML (27.5%) patients revealed abnormal aCGH
findings. In BMSCs, only 1 MDS patient (R86) had abnormal
aCGH findings, which included an extra chromosome 5 and
the loss of the short arm of chromosome X (Fig. 2a). In the
HCs of one AML patient (A106), aCGH detected the loss of
chromosome 7 and additional genetic abnormalities that
were not observed by karyotyping, but it did not detect
numerical aberrations in the corresponding BMSCs (Fig. 2c).
This may have occurred because aCGH cannot sufficiently
detect a low proportion of cells with abnormalities (low
mosaicism) and balanced translocations. However, aCGH
detected additional copy number aberrations that were not(c)
⑤
②
④
tion (FISH) and array comparative genomic hybridization (aCGH)
and abnormal karyotype of bone marrow stromal cells (BMSC)
(R86). Patient's aCGH of chromosome 5 (lower). HC with normal
karyotype of HC (upper) and trisomy 5 of BMSC (medium) from a
ISH of chromosome 5 revealed normal pattern of 2 green signals
bnormal (3G3R in ③, 3G2R in ④) and normal (⑤) in BMSC. (c)
icism of trisomy 5 and dicentric (1;19) in BMSC (medium) from a
(lower). HC showing loss of whole chromosome 7 and BMSC with
182 Y. Kim et al.observed by conventional cytogenetics because it has a higher
sensitivity than karyotyping (Supplementary Table S3).
Epigenetic abnormalities in BMSCs from patients
with MDS and AML
Global methylation was quantitatively determined by LINE-1
pyrosequencing. The LINE-1 methylation percentage in the
patient BMSCs was significantly lower than that in the control
BMSCs (68.2 ± 3.8 vs. 72.9 ± 3.4, P b 0.001) (Fig. 3a). The
LINE-1 methylation percentage in BMSCs was typically lower
than that in the corresponding HCs (68.2 ± 3.8 vs. 71.5 ± 6.0,
P = 0.001), whose proportion significantly correlated with
each other (r = 0.722, P b 0.001) (Fig. 3a). For the BMSCs of
the AML patients, significant LINE-1 hypomethylation was
observed compared with the control BMSCs (67.9 ± 3.8,
P b 0.001). However, in MDS patients, this difference was
not statistically significant (69.4 ± 4.2, P = 0.152) (Fig. 3b).
We chose CDKN2B as a marker for local methylation
because CDKN2B is a commonly methylated gene in HCs
of MDS and AML. The CDKN2B methylation percentages in
patient BMSCs were not different from those in the normal
controls (4.2 ± 4.7 vs. 4.2 ± 1.5). The CDKN2B methylation
percentages were higher in HCs (11.2 ± 10.2) than in BMSCs
(P b 0.001), and the CDKN2Bmethylation percentages in HCs
and BMSCs were significantly correlated with each other
(r = 0.517, P = 0.003) (Supplementary Fig. S2).
Discussion
In this study, we evaluated the genetic and epigenetic changes
in BMSCs from patients diagnosed with MDS and AML, and we
compared these results with those obtained from control
BMSCs derived from healthy donors. Patient BMSCs had lower
proliferative activity than controls, which was confirmed by
growth kinetics. The proliferative activity of patient BMSCs
was dramatically decreased after the 3rd passage. This retarded
proliferation was explained by SA-β-gal staining, which indicat-
ed that senescence had occurred in the greater part of patient
BMSCs at an earlier passage than in the controls. This is one of60
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Figure 3 Comparison of methylation status between hematopo
Correlation of LINE-1 methylation between HCs and BMSCs (P b
myelodysplastic syndrome and acute myeloid leukemia patient HCsthe reasons that we did not obtain enough metaphase cells for
karyotyping from approximately 10% of the patient samples.
Results from this study have indicated that cytogenetic
abnormalities are more frequent in patient BMSCs than in
controls. Approximately 5% of patients were found to have
clonal cytogenetic abnormalities, the most common of which
was an extra chromosome 5. None of the observed cytogenetic
abnormalities in BMSCs were the same as those found in HCs.
Additionally, there were more genetic changes in the BMSCs of
AML patients than in the BMSCs of MDS patients.
A previous study reported karyotype abnormalities in four
out of 13 MDS patients (trisomy 5 and 7) compared with one
out of five healthy individuals (trisomy 5) (Klaus et al.,
2010). Another study found similar abnormalities in chromo-
some 5 in cultured BMSCs produced in cell therapy facilities.
Those authors commented that the occurrence of aneuploi-
dy in cultured BMSCs was not related to the culture process
but could be donor dependent (Tarte et al., 2010). These
changes in chromosome number and structure were major
contributors to the genomic instability of BMSC, which is
induced by cellular aging rather than oncogenic transforma-
tion (Estrada et al., 2013; Tarte et al., 2010). The proportion
of metaphase cells with chromosomal aberrations was low;
thus, genetic abnormalities were more easily detected by
cytogenetics and FISH methods than by aCGH. On the other
hand, aCGH has higher resolution; thus, more genetic
changes can be recognized by aCGH than by other methods.
Another potential source of genomic instability is epigenetic-
induced reductions in the expression of DNA repair genes.
Commonly observed changes in DNA methylation are global
hypomethylation, including repetitive element hypomethyla-
tion, and focal hypermethylation of promoter CpG islands. In
this study, we analyzed methylation of the LINE-1 repetitive
elements and CDKN2B as surrogate markers of global genomic
and focal methylation, respectively (Yang et al., 2004) and
identified global hypomethylation in patient BMSCs. LINE-1 is
a repetitive element that constitutes 17–25% of the human
genome (Deininger et al., 2003; Lander et al., 2001), is variably
hypomethylated in cancers, and is associated with microsatel-
lite instability (Estécio et al., 2007). In this study, the LINE-1
methylation level in patient HCs was comparable with that inP<.001
P=.002
ietic cells (HCs) and bone marrow stromal cells (BMSCs). (a)
0.001). (b) The percentage of LINE-1 methylation in control,
and BMSCs.
183Genetic and epigenetic alterations of bone marrow stromal cellshealthy controls, and this finding was consistent with results
from a previous study (Kroeger et al., 2008). Global LINE-1
hypomethylation can repress genome-wide gene expression
(Aporntewan et al., 2011); therefore, we postulated that LINE-1
hypomethylation in patient BMSCs may be one of the causative
factors of impaired stromal support and the resultant ineffec-
tive hematopoiesis in those patients (Geyh et al., 2013). It is
notable that LINE-1 was hypomethylated in AML patient BMSCs
compared with their corresponding HCs and control BMSCs. In
MDS patient BMSCs, a similar phenomenon was observed but
it was not statistically significant. This may have occurred
because MDS is a heterogeneous spectrum of disorders. Some of
them progress into AML which are considered preleukemic. The
quantitative measurement using pyrosequencing technique
can easily discriminate this difference and may indicate that
the level of global LINE-1 methylation is associated with the
initiation and progression of MDS and AML. In addition, these
results were partially supported by the hypotheses that
leukemic cells disrupt niche signaling and that niche
changes promote leukemogenesis (Raaijmakers, 2011). In
vitro studies using co-culture methods revealed that stromal
cells could alter their behavior, resulting in increased prolifer-
ation and altered cytokine profiles of leukemic cells (Bruserud
et al., 2004; Hatfield et al., 2006).
In summary, our data demonstrated that BMSCs from
patients with MDS and AML are genetically and epigeneti-
cally altered. Cytogenetic abnormalities developed more
frequently in patient BMSCs than in healthy control BMSCs;
they developed due to genomic instability, and they induced
cellular senescence. Epigenetic alterations in patient BMSCs
were characterized by global hypomethylation represented
by LINE-1 gene hypomethylation. The epigenetic changes
were more severe in the BMSCs of AML patients than in the
BMSCs of MDS patients. Further studies including functional
investigations will enhance our understanding of the effects
of genomic instability in BMSCs and their potential as a
therapeutic target.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2015.01.004.
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